Get Connected:


Latest News

Single-Sample Confirmatory Diagnosis of Diabetes Tops AJPB Week in Review
Top news of the week from The American Journal of Pharmacy Benefits.
Senseonics was granted FDA approval for the Eversense Continuous Glucose Monitoring (CGM) system’s use in people 18 years of age and older with diabetes. 
Top news of the day from across the health care landscape
While normally a diabetes diagnosis requires multiple sample confirmations from blood work of elevated hemoglobin A1C (HbA1C) or glucose, new data has shown that a single-sample confirmatory diagnosis of diabetes may be possible.
Top news of the day from across the health care landscape
The updated label includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
Employers that offer healthcare benefits, paid sick days, and disability insurance benefits will spend about $84,000 in annual migraine-related costs for every 1000 employees.
Top news of the day from across the health care landscape
View More >

From the Journals

New proposed rules for the Medicare Part D drug program could affect the manner in which pharmacy benefit managers administer the program and could impact profitability.
Healthcare stakeholders must evaluate how to use resources more efficiently as it has become clear that driving down prices in one segment of care has not improved medical outcomes for the majority of patients.
This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
An estimation and comparison of the cost of home phototherapy versus biologics over a 3-year time horizon in patients with moderate-to-severe plaque psoriasis.
The study found no mean difference in all-cause healthcare costs for patients with newly diagnosed nonvalvular atrial fibrillation initiating treatment with dabigatran versus warfarin.
Buprenorphine treatment with and without induction was found to decrease costs and utilization in opioid-dependent benefciaries.
Focusing on cost alone could diminish the vital service aspects behind successfully caring for a patient in a specialty pharmacy.
Upcoming Partner Events